title: NSCLC drug targets acquire new visibility.
authors.forename: M J
authors.initials: MJ
authors.lastname: Friedrich
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D000077610:Bexarotene; D014408:Biomarkers, Tumor / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D000077547:Crizotinib; D066246:ErbB Receptors / Q000187:drug effects / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation / Q000187:drug effects; D009536:Niacinamide / Q000031:analogs & derivatives; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D010671:Phenylurea Compounds; D010880:Piperidines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000077157:Sorafenib; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: C517975:AZD 6244; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D001562:Benzimidazoles; D014408:Biomarkers, Tumor; C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D010671:Phenylurea Compounds; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D011799:Quinazolines; D013764:Tetrahydronaphthalenes; D009536:Niacinamide; D000077547:Crizotinib; D000077157:Sorafenib; D000077610:Bexarotene; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib; C452423:vandetanib